Human Immunodeficiency Virus – Executive Insights – Human Immunodeficiency Virus Executive Insights
HIV is a deadly viral infection that impairs cells of the immune system and progressively destroys the body’s ability to fight infections. Availability of multiple therapeutic agents for maintaining low viral loads has been fundamental to treatment of HIV. Treatment consists of antiretroviral therapy (ART), and patients are mostly treated with a three-drug pharmacological regimen in combination (often in one pill), with the INSTI-based STRs most prescribed among interviewed KOLs. Among currently available therapies, Biktarvy (BIC/FTC/TAF) is the most preferred drug, except in patients of childbearing age. Newer agents such as Trogarzo (IBA) and Rukobia (FTR) are being used mainly in patients with an MDR infection. Although the most awaited late-phase pipeline agents, Merck & Co.’s islatravir and Gilead Sciences’ lenacapavir, offer a distinct advantage of being longer acting, which will help with long-term adherence to treatment, a cure remains the ultimate goal for treatment of HIV. Discovery and development of latency-reversing agents, immune modulators, and genetically engineered effector antibodies, as well as therapeutic vaccines, will be critical for the future.
QUESTIONS ANSWERED
- What is the prevalence of HIV by race / ethnicity or by transmission type? How are U.S. patients managed today for the treatment of HIV?
- What are the key areas of unmet need and opportunities in the prevention and management of HIV?
- Which therapies are in late-phase of development for HIV? What is the potential impact of new launches and how will these therapies affect future opportunity in the treatment of HIV?
- What are the key drivers and limiters of the market today and in the future?
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Sayani Datta, M.Sc., Lead Healthcare Research & Data Analyst – Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders. Sayani’s primary areas of focus are nonalcoholic steatohepatitis (NASH) and pulmonary hypertension (PH). Previously, she was an associate consultant with IQVIA. She has worked on various types of custom and syndicated research projects in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, commercial opportunity assessments, and market tracking and intelligence. She is an M.Sc. in biotechnology from the University of Leeds, where she gained exposure to life sciences research and development working as a postgraduate research intern.
Shilpa Verma, B.Pharm., Manager, Healthcare Research & Data Analytics, Infectious, Niche, and Rare Diseases. She has more than 11 years of work experience in competitive intelligence and medical affairs. Her expertise is in infectious diseases and immuno-inflammatory diseases. She received her bachelor’s degree in pharmacy from the Indian Institute of Technology at Banaras Hindu University. She also has a postgraduate degree in business management from the Narsee Monjee Institute of Management Studies.
Prior to joining Clarivate, Ms. Verma worked for WNS and Evalueserve, where her clients included leading pharmaceutical companies. She is also an expert in HIV. She did her internship at AstraZeneca and has experience working in the quality control department.